Patient-reported outcomes in the single-tablet regimen (STaR) trial of rilpivirine/emtricitabine/tenofovir disoproxil fumarate versus efavirenz/emtricitabine/tenofovir disoproxil fumarate in antiretroviral treatment-naive adults infected with HIV-1 through 48 weeks of treatment-Reference-Cited by-同舟云学术

Patient-reported outcomes in the single-tablet regimen (STaR) trial of rilpivirine/emtricitabine/tenofovir disoproxil fumarate versus efavirenz/emtricitabine/tenofovir disoproxil fumarate in antiretroviral treatment-naive adults infected with HIV-1 through 48 weeks of treatment

Published:2015-10-21 Issue:3 Volume:28 Page:401-408
ISSN:0954-0121
Container-title:AIDS Care
language:en
Short-container-title:AIDS Care

Author:

Wilkins Ed L.,Cohen Calvin J.,Trottier Benoit,Esser Stefan,Smith Don E.,Haas Bernhard,Brinson Cynthia,Garner Will,Chuck Susan,Thorpe David,De-Oertel Shampa

Funder

Gilead Sciences

Publisher

Informa UK Limited

Subject

Public Health, Environmental and Occupational Health,Social Psychology,Health (social science)

Link

http://www.tandfonline.com/doi/pdf/10.1080/09540121.2015.1096890

Reference41 articles.

1. The impact of specific HIV treatment-related adverse events on adherence to antiretroviral therapy: A systematic review and meta-analysis

2. Single-tablet regimens in HIV: does it really make a difference?

3. Self-Reported Symptoms and Medication Side Effects Influence Adherence to Highly Active Antiretroviral Therapy in Persons With HIV Infection